The MagPro R30 is our most popular TMS device and is favoured by both private and NHS clinics across the United Kingdom. It has an advanced high performance magnetic stimulator designed for clinical use. Clinicians report that the Super Flex arm allows ease of use and accurate coil positioning. The cooled coil ensures patient safety and comfort. The MagPro R30 performs repetitive Transcranial Magnetic Stimulation (rTMS) and runs many complex protocols successively (up to 20,000 pulses).
The MagVita range of magnetic stimulators are the only TMS devices available in the UK that are CE approved for clinical use for the treatment of depression.
- “treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode"
Examination of the physiology of the motor pathways in the central and peripheral nervous system
Is often used within Transcranial Magnetic Stimulation (TMS) and repetitive Transcranial Magnetic Stimulation (rTMS) research
Stimulation rates up to 30 pulses per second.
60 pps option available.
System operation control via a built-in computer, eliminating the need for an external computer to set up and control the timing of stimulus sequences.
Flexible protocol storage.
User friendly software.
Quick protocol set-up and storage.
Easily connected to external equipment (like EMG system) via the In/Out triggers.
For more information about TMS for your hospital or clinic please fill out the contact form below or email email@example.com
In December 2015, the National Institute for Health and Care Excellence (NICE) approved rTMS (Repetitive Transcranial Magnetic Stimulation) as an effective and safe method of treating depression for patients in the UK. Repetitive Transcranial Magnetic Stimulation (rTMS) is a treatment which uses pulsing magnetic fields to activate brain centers associated with mood. The treatment has a number of advantages over traditional medication as it is non-invasive. It does not involve surgery, anesthesia or sedation and it does not have the side effects associated with antidepressants. rTMS has also been shown effective in treating migraine, post-natal depression and pain.
The evidence on repetitive transcranial magnetic stimulation for depression shows no major safety concerns [...] repetitive transcranial magnetic stimulation for depression may be used with normal arrangements for clinical governance and audit.”
Ectron is pleased to announce the launch of Tyromotions new PABLO which is being demonstrated for the very first at RehabWeek 2017, in London.
system is a modern assessment and therapy device for the rehabilitation of patients with impaired motor functions.
MINIMAL MOVEMENTS BECOME VISIBLE
The sensitivity of the Motion sensors enables the tracking of underlying movements. Patients who perform a therapeutic game with minimal movements are more motivated and have more fun during the rehabilitation process.
Activities of daily living can be implemented into the therapy sessions at a high rate of repetition with the PABLO® system. This link to daily routines supports the motivation of the patient and enables his/her motor learning. Sit-to-stand, steering a car, reaching for objects or climbing the stairs are just a few examples.
Creativity has no limits! In combination with the TYROS software every therapeutic movement-exercise can be done in a motivating way and additional feedback using the PABLO® Motionsensors. It‘s simple handling enables a very quick therapy setup with almost no chances for compensation movements.
For more information about the new PABLO please click here
or email firstname.lastname@example.org
Ectron is proud to partner with Dudley and Walsall Mental Health Partnership NHS Trust in the launch of it's TMS clinical trials.
The team from Ectron along with Claus Mathiesen from MagVenture spent two days at the Dorothy Pattison Hospital in Walsall covering the benefits of TMS Therapy for the treatment of depression along with sharing the latest TMS research.
In addition, the whole team gained an understanding of what TMS can offer as a treatment, who it may be suitable for, as well as a practical "hands-on sessions" with the MagVita TMS Therapy system.
Dr Russell Davies and the team will now be going forward and the trial is due to start this month.
For more information about TMS training for your hospital or NHS trust, please call 0117 941 3979 or email: email@example.com alternatively you can complete our contact form
5th Annual Queen Square Upper Limb Neurorehabilitation Course, London 29th-30th June 2017.
Ectron are pleased to announce it is sponsoring the 5th Annual Queen Square Upper Limb Neurorehabilitation Course, London 29th-30th June 2017.
5th Annual Queen Square Upper Limb Neurorehabilitation Course: Treating patients with upper limb deficit: Integrating research into practice
The two-day course provides an overview of current research looking at treatment and rehabilitation options for the neurological patient with upper limb deficit. The course aims to assist in the practical real-life translation of scientific evidence into clinical practice and asks - what is it that makes an upper limb therapy effective? Delegates will have the opportunity to trial novel devices and robotic technology.
Course lecturers are from The National Hospital for Neurology and Neurosurgery, the UCL Institute of Neurology and other renowned institutes in upper limb rehabilitation in neurological patients.
This year the team took delivery of the latest in technology from Tyromotion and have full Tyrosolution including MYRO at the hospital to complete the Upper Limb Suite. The National Hospital for Neurology and Neurosurgery are seeing fantastic results with their patients and continued benefits are often seen for at least 6 months beyond the programme.